drugset
drugset / Trial / NCT06374173

A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT06374173 ↗

Phase 1 Recruiting 123 enrolled Hefei TG ImmunoPharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1 Study to Evaluate TGI-6 in Subjects with Locally Advanced/Metastatic Solid Tumors

Timeline

Start
2024-01-03
Primary completion
2027-09
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TGI-6 Unknown — Intravenous

Indications

No indication recorded.